JPRN-UMIN000010997
Not yet recruiting
未知
Intravitreal aflibercept injection for exudative age-related macular degeneration - Intravitreal aflibercept injection for AMD
Department of Ophthalmology, Fukushima Medical University School of Medicine0 sites50 target enrollmentJune 19, 2013
ConditionsAge-Related Macular Degeneration
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Age-Related Macular Degeneration
- Sponsor
- Department of Ophthalmology, Fukushima Medical University School of Medicine
- Enrollment
- 50
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)The greatest linear dimension (GLD)\>12 Macular Photocoagulation Study Disc Areas 2\)Presence of subretinal hemorrhage, scar or macular fibrosis(\>50% lesion area) 3\)Prior treatment with anti\-VEGF drugs, photodynamic therapy 4\)Prior treatment with dexamethasone(within 6 months) or triamcinolone (within 30 days), intraocular surgery(within 3 months 5\)Active intraocular inflammation 6\)Hypersensitivity or allergy to fluoresceinor or indocyanine green, clinically significant drug allergy or known hypersensitivity to therapeutic or diagnostic protein products 7\)Patients who the doctor in charge judges are ineligible for the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Study of intravitreal aflibercept for exudative age-related macular degeneratioAge-related macular degenerationJPRN-UMIN000012126Department of Ophthalmology, Jikei University School of Medicine30
Not yet recruiting
Phase 3
To investigate the role of Intravitreal Aflibercept (Eylea) in the treatment of patients whose wet Age related Macular degeneration is not adequately controlled with conventional anti VEGF (intravitreal Avastin or Lucentis) treatment.ACTRN12613001020774Greenlane Clinical Centre Auckland District Health Board50
Completed
Phase 4
The study of Intravitreal aflibercept with treat and extend regimen for macular edema with branch retinal vein occlusion (BRVO)Branch retinal vein occlusionJPRN-UMIN000023200Department of Ophthalmology, Akita University50
Completed
Not Applicable
Intravitreal injection of anti vascular endothelial growth factor agent, Lucentis (ranibizumab), for the treatment of retinopathy of prematurityretinopathy of prematurityJPRN-UMIN000013975agoya University hospital ophtalmoligy30
Completed
Not Applicable
Combination therapy of intravitreal aflibercept and topical bromfenac for RVOretinal vein occlusionJPRN-UMIN000022988Juntendo Urayasu Hospital40